Radiopharm Theranostics Limited (RADX) Stock Forecast
RADX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.80 / 5 from 5 analysts
- Price target
- $16.95 average of analyst targets
- Upside to target
- +1,546.1% from the latest close
- Next earnings
- —
- 52-week range
- $1.03 – $10.63
RADX analyst ratings
5 analystsNumber of analysts at each rating.
RADX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RADX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (FY2027) | −$3.23 | −$3.23 | −$3.23 | −$5.53 | +41.6% | 1 |
| Next fiscal year (FY2028) | −$2.64 | −$2.64 | −$2.64 | −$3.80 | +30.4% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RADX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current fiscal year (FY2027) | $1.1M | $0 | $2.3M | −46.6% | 5 |
| Next fiscal year (FY2028) | $23.8M | $1.8M | $47.6M | +2,133.7% | 3 |
RADX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RADX revenue: reported and forecast
RADX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (FY2027) | −$3.66 | −$3.66 | $0.00 | $0.00 | −$3.23 | −11.7% | 0 up · 0 down |
| Next fiscal year (FY2028) | −$1.82 | −$1.82 | −$1.82 | −$1.82 | −$2.64 | +45.0% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RADX earnings surprises
Reported EPS vs the consensus estimate for the last 5 quarters; RADX beat in 1 of 5.
What analysts expect from RADX
5 analysts cover Radiopharm Theranostics Limited; their consensus rating is strong buy (4.80 on a 1–5 scale, where 5 is a strong buy). The average price target is $16.95, 1,546.1% above the latest close of $1.03. Analysts expect earnings of −$3.23 per share for FY2027, +41.6% from a year earlier. For FY2028 the average estimate is −$2.64 per share on revenue of $23.8 million. Radiopharm Theranostics Limited beat the EPS estimate in 1 of the last 5 quarters.
Related: RADX income statement, RADX chart. See the RADX stock overview for the latest quote and news.
RADX forecast FAQ
What is Radiopharm Theranostics Limited's price target?
The average analyst price target for Radiopharm Theranostics Limited is $16.95, 1,546.1% above the latest close of $1.03.
Is Radiopharm Theranostics Limited a buy, hold or sell?
Of 5 analysts covering Radiopharm Theranostics Limited, 4 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Radiopharm Theranostics Limited's EPS forecast?
Analysts forecast −$3.23 per share for FY2027 (range −$3.23 to −$3.23); for FY2028 the estimate is −$2.64.
What is Radiopharm Theranostics Limited's revenue forecast?
The average revenue estimate for FY2027 is $1.1 million, growth of −46.6%; for FY2028 it is $23.8 million.
Does Radiopharm Theranostics Limited usually beat earnings estimates?
Radiopharm Theranostics Limited reported EPS at or above the analyst estimate in 1 of the last 5 quarters.